Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted and appeared in  CardiovascularBG ControlPublic HealthIssue 638

Intensive Risk Management May Have No Effect

Intensively managing risk factors in patients newly diagnosed with diabetes in primary care does not have any significant effect on their cardiovascular outcomes compared with usual care.... 

The study found patients treated to tough HbA1c, cholesterol and blood pressure targets did not have significantly different risks of cardiovascular events after five years compared with those receiving standard diabetes care from GP practices.

The study provides further evidence to undermine moves to intensify diabetes treatment early on and provides evidence that standard GP care may be sufficient to prevent an increase in cardiovascular risk.

NICE raised the QOF HbA1c target in 2010 for patients with type 2 diabetes from 7.5% (58mmol/mol) to 7% (53mmol/mol), conceding that there was sufficient 'uncertainty' about patient safety to justify the move.

An analysis published in June also found aggressively lowering blood glucose in patients with type 2 diabetes only slightly reduces the risk of developing neuropathy, but greatly increased the risk of hypoglycemia.

This study finds that aggressive management to keep HbA1c levels below 7% (53mmol/mol), blood pressure below 135/85 mmHg, cholesterol below 5mmol/l and prescribing aspirin to those treated with antihypertensive medication did not significantly reduce their likelihood of having a cardiovascular event.

The research involved 379 general practices in Denmark, the Netherlands and the cities of Cambridge and Leicester, with each practice randomized to provide routine care after screening patients for diabetes or intensive multifactorial treatment. Over 3,000 patients without a history of ischemic heart disease were included in the final analysis, all aged between 40 and 69 years.

Routine care consisted of a standard pattern of diabetes care according to current recommendations applicable in each center. All patients with a cholesterol level over 3.5mmol/l were prescribed a statin.

Over five years, researchers found non-significant reductions in risk of 17% for a first cardiovascular event from diagnosis when comparing intensive treatment to routine care, and 30% for a second cardiovascular event.

When restricting cardiovascular events to include mortality, non-fatal myocardial infarction and non-fatal stroke, the risk reduction was only 14% when comparing the two groups.

The study authors concluded: "Early intensive multifactorial treatment was not associated with a significant reduction in total cardiovascular burden at five years."

"It remains to be seen whether intensification of early treatment in screen-detected individuals might translate into improved outcomes in the longer term."

Professor Mike Kirby, a GP in Radlett who participated in the study, said the results show that most practices were taking the right approach with their patients.

He said: "The standard of care was already good in most of the control practices, and this makes it difficult to show a difference."

"The use of statins, good blood pressure control and prescription of metformin made the difference, in my opinion."

But Dr. Roger Gadsby, a GP in Nuneaton and member of the NICE type 2 diabetes guideline development group, said the study follow-up period was too short to show positive outcomes.

He said: "In some intervention studies it can take up to 10 years for benefits to be demonstrated and so this negative result might just reflect the five years of the study."

"There is evidence early intensive glycemic control improves cardiovascular outcomes in the long term, but they were looking at 10-plus years of follow-up after the intervention."

Risk reductions for cardiovascular events comparing intensive treatment with routine care showed that, First event – 17%; Second event – 30%; Any event – 23%

 Diabetic Medicine 2012, online 23 July 



Bookmark and Share | Print | Category | Home

This article originally posted 09 August, 2012 and appeared in  CardiovascularBG ControlPublic HealthIssue 638

Past five issues: Diabetes Clinical Mastery Series Issue 247 | Issue 787 | Diabetes Clinical Mastery Series Issue 246 | SGLT-2 Inhibitors Special Edition June 2015 | Issue 786 |

2015 Most Popular Articles:

Triple Therapy Improves Glycemia in Type 1 Diabetes
Posted June 19, 2015
A Dual SGLT1/SGLT2 Inhibitor Can be a Treatment Option in Type 1 Diabetics
Posted June 12, 2015
Canagliflozin and Its Effects on Weight Loss and BP
Posted June 12, 2015
Efficacy and Safety of an SGLT-2 Inhibitor with Insulin for Type 2s
Posted May 28, 2015
High Fiber Diets Reduce Risk of Diabetes
Posted June 04, 2015
Skin Bacteria a Cause of Diabetes?
Posted June 12, 2015
Blood Biomarkers May Predict Risk of Severe Hypoglycemia
Posted June 12, 2015
Lilly Insulin: A Better Alternative than Lantus?
Posted June 19, 2015
Are Postprandial Levels in T1 Patients Impacted by More Than Carbohydrates?
Posted May 28, 2015
Tight Blood Glucose Control and Cardiovascular Disease
Posted June 12, 2015

Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Richard K. Bernstein, MD | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
Have you recommended the use of an SGLT-2 inhibitor to any of your type 1 patients?

CME/CE of the Week
John Steinberg, DPM

Category: Diabetic Foot